News
Valbiotis präsentiert weitere positive Ergebnisse aus der klinischen HEART-Studie zu TOTUM•070 gegen Hypercholesterinämie
Valbiotis (FR0013254851 – ALVAL, qualifiziert für PEA/SME) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung
Valbiotis Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA for Autosomal-Dominant Polycystic Kidney Disease (ADPKD)
POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
EQS-News: ABIVAX ANNOUNCES THE RELEASE OF ITS 2022 HALF-YEAR FINANCIAL REPORT
FITCH ASSIGNS AN INVESTMENT GRADE BBB- RATING TO KAUFMAN & BROAD
Key Skills for Sustainable Innovation in Manufacturing Revealed in Study from Dassault Systèmes
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) today revealed key skills to accelerate the manufacturing sector’s transformation to create sustainable experiences. Design for
Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022
Regulatory News:
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
EQS-News: ABIVAX ABSTRACT ON OBEFAZIMOD PHASE 2B RESULTS SELECTED FOR MODERATED POSTER PRESENTATION AT UEG WEEK 2022
R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, will host today an R&D event for investors
Private Equity Women Investor Network Names Eurazeo 2022 International General Partner of the Year
Eurazeo, a leading global investment company with a diversified portfolio of €32.5 billion in assets under management, today announced that it was named the 2022 International General Partner of
Sensorion to Participate in Various Upcoming Investor Conferences
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022
Regulatory News:
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Sensorion Reports 2022 First Half Results
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy
Regulatory News:
NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities
Poxel Reports Financial Results for First Half 2022 and Provides a Corporate Update
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-stereoisomer of Pioglitazone
POXEL SA (Euronext : POXEL - FR0012432516), clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including
BIOCORP gibt anlässlich der EASD-Jahrestagung die CE-Kennzeichnung von SoloSmart® bekannt, einem medizinischen Hilfsmittel für SANOFI Solostar®-Pens
fcAufsichtsrechtliche Meldungen:
BIOCORP (FR0012788065 – ALCOR / PEA‐PME-qualifiziert), ein französisches Unternehmen, das auf die Konzeption, Entwicklung und Herstellung von innovativen
BIOCORP announces the CE marking of SoloSmart®, an accessory medical device for SANOFI Solostar® pens at the occasion of EASD
Regulatory News:
BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, and SANOFI announced
Streamkeeper von Verimatrix erzielt höchste Auszeichnung bei den CSI Awards 2022
Verimatrix (Euronext Paris: VMX) (Paris:VMX), der führende Anbieter von kundenorientierten Sicherheitslösungen für die moderne vernetzte Welt, gab heute bekannt, dass seine Lösung Verimatrix
Verimatrix Streamkeeper Takes Home Top Honor in 2022 CSI Awards
Regulatory News:
Verimatrix, (Euronext Paris: VMX) (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that Verimatrix Streamkeeper was
DGAP-News: Abivax presents first-half 2022 financial results and operations update
EUTELSAT KONNECT satellite selected by Liquid Intelligent Technologies for broadband connectivity services across Uganda, South Sudan and the Democratic Republic of Congo
Regulatory News:
Eutelsat Communications (Euronext Paris: ETL) and Liquid Intelligent Technologies (Liquid), a business of Cassava Technologies, a pan-African technology group, have signed a
Verimatrix-Technologien zur Bedrohungsabwehr im Einsatz bei führendem Online-Shopping-Service Saudi-Arabiens
Verimatrix (Euronext Paris: VMX), der führende Anbieter von kundenorientierten Sicherheitslösungen für die moderne vernetzte Welt, teilte heute mit, dass Jarir, Saudi-Arabiens größter E-Commerce-
Valbiotis informiert über seine Fortschritte und veröffentlicht seinen Finanzbericht für das erste Halbjahr 2022
Valbiotis (FR0013254851 – ALVAL/PEA/KMU-berechtigt) (Paris:ALVAL), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und Bekämpfung von
Valbiotis Provides an Update on Its Progress and Publishes Its Financial Report for the First Half of 2022
Regulatory News:
Valbiotis (FR0013254851 – ALVAL / PEA/SME eligible) (Paris:ALVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic